Patent intelligence · US
US 8618058
Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity
Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity
Patent details — US 8618058
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 31, 2013
- Expiration
- Dec 26, 2033
- Applicant
- Soricimed Biopharma Inc.
- Claims
- 18
- CPC classes
- A61K, A61K31/337, A61K31/555, A61K38/00
Quick answer
US 8618058 (Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity) is held by Soricimed Biopharma Inc.. Status: granted. Granted Dec 31, 2013. Expires Dec 26, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Soricimed Biopharma Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/337, A61K31/555, A61K38/00, A61K38/1761, A61P
More from Soricimed Biopharma Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12312339
Polo like kinase 4 inhibitors
granted -
US 12239729
TRPV3 agonists for the treatment of skin conditions
granted -
US 12054556
Anti-PD-L1 antibody and use thereof
granted -
US 12018043
CD73 inhibitors
granted -
US 12005080
Method for promoting proliferation of immune cells
granted -
US 11993655
Anti-PD-L1 antibody and use thereof
granted -
US 11858915
Polo like kinase 4 inhibitors
granted -
US 11807658
CD73 inhibitors
granted
Frequently asked questions
What is US patent 8618058?
US 8618058 (Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity) is held by Soricimed Biopharma Inc.. Status: granted. Granted Dec 31, 2013. Expires Dec 26, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8618058?
Soricimed Biopharma Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 52 pharmaceutical patents for this assignee.
When does US 8618058 expire?
Our index shows an expiration date of Dec 26, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.